Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid th...
| Class:Id | Summation:9684956 |
|---|---|
| _displayName | Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid th... |
| _timestamp | 2021-03-04 10:32:23 |
| created | [InstanceEdit:9684954] Jassal, Bijay, 2020-04-22 |
| modified | [InstanceEdit:9690448] Jassal, Bijay, 2020-06-01 [InstanceEdit:9717106] Stephan, Ralf, 2021-03-04 |
| text | Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that regulates a diverse range of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. S1P receptor 1 (S1PR1) agonists possess immunomodulatory/immunosuppresant actions. The S1PR1 agonists fingolimod (FTY720) (Chun & Hartung 2010), siponimod (BAF312) (Pan et al. 2013, Glaenzel et al. 2018) and ozanimod (Scott et al, 2016) are effective immunology modulators which are widely used in the treatment of multiple sclerosis. Fingolimod is being investigated in the management of inflammation caused by COVID-19 (Phase 2 study NCT04280588). |
| (summation) | [Reaction:9678854] S1PR1 binds S1PR1 agonists [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid th... (9684956)
